Overview

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Status:
Withdrawn
Trial end date:
2023-10-03
Target enrollment:
Participant gender:
Summary
To find a recommended dose of mosunetuzumab that can be given to patients with ALL.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Genentech, Inc.